Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,287,381 papers from all fields of science
Search
Sign In
Create Free Account
UK 68798
Known as:
UK-68,798
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
dofetilide
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
1995
Highly Cited
1995
Electrophysiologic profile and efficacy of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with sustained monomorphic ventricular tachycardia. Dofetilide…
Yaves Bashir
,
P. Thomsen
,
+7 authors
A. Camm
American Journal of Cardiology
1995
Corpus ID: 23721924
1994
1994
Antifibrillatory effects of clofilium in the rabbit isolated heart
G. Friedrichs
,
L. Chi
,
A. Green
,
B. Lucchesi
British Journal of Pharmacology
1994
Corpus ID: 1960548
1 This study was designed to determine whether clofilium exhibits antifibrillatory activity in a pinacidil + hypoxia‐induced…
Expand
Highly Cited
1993
Highly Cited
1993
Comparative Assessment of Ibutilide, D‐Sotalol, Clofilium, E‐4031, and UK‐68, 798 in a Rabbit Model of Proarrhythmia
L. V. Buchanan
,
G. Kabell
,
M. Brunden
,
J. K. Gibson
Journal of Cardiovascular Pharmacology
1993
Corpus ID: 22895631
Summary Class III agents have been associated with development of a polymorphic ventricular tachycardia (PVT) known as torsades…
Expand
Highly Cited
1993
Highly Cited
1993
Electrophysiological and inotropic effects of H 234/09 (almokalant) in vitro: a comparison with two other novel IK blocking drugs, UK-68,798 (dofetilide) and E-4031.
C. Abrahamsson
,
G. Duker
,
C. Lundberg
,
L. Carlsson
Cardiovascular Research
1993
Corpus ID: 36550308
OBJECTIVE The aim was to compare the electrophysiological and inotropic effects of the novel class III agents H 234/09, UK-68,798…
Expand
1993
1993
Differential Class III and glibenclamide effects on action potential duration in guinea‐pig papillary muscle during normoxia and hypoxia/ischaemia
I. Mackenzie
,
V. L. Saville
,
J. F. Waterfall
British Journal of Pharmacology
1993
Corpus ID: 20896431
1 Microelectrode recording techniques were used to study the effects of several potassium channel blockers which are considered…
Expand
1992
1992
Class III Antiarrhythmic Action and Inotropy: Effects of Dofetilide in Acute Ischemic Heart Failure in Dogs
E. Mortensen
,
Tao Yang
,
H. Refsum
Journal of Cardiovascular Pharmacology
1992
Corpus ID: 39263805
Summary We studied the hemodynamic and metabolic effects of the novel class III antiarrhythmic agent dofetilide (UK-68,798) in…
Expand
1992
1992
Electromechanical Action of Dofetilide and D-Sotalol During Simulated Metabolic Acidosis in Isolated Guinea Pig Ventricular Muscle
Tao Yang
,
P. Tande
,
H. Refsum
Journal of Cardiovascular Pharmacology
1992
Corpus ID: 30165485
Summary: We examined the electromechanical effects of two class III antiarrhythmic agents, dofetilide (UK-68,798) and D-sotalol…
Expand
1992
1992
Effects of altered extracellular potassium and pacing cycle length on the class III antiarrhythmic actions of dofetilide (UK-68,798) in guinea-pig papillary muscle
Tao Yang
,
P. Tande
,
D. Lathrop
,
H. Refsum
Cardiovascular Drugs and Therapy
1992
Corpus ID: 993196
SummaryThe effects of altered extracellular K+ concentrations ([K+]0) and pacing cycle lengths (CLs) on the electrophysiological…
Expand
1991
1991
Measurement of the class III antidysrhythmic drug, UK-68,798, in plasma by radioimmunoassay.
D. Walker
,
G. Aherne
,
+5 authors
W. Wild
Journal of Pharmaceutical and Biomedical Analysis
1991
Corpus ID: 38744189
1991
1991
A dose-ranging study of UK-68,798, a novel class III anti-arrhythmic agent, in normal volunteers.
JD Gemmill
,
CA Howie
,
+4 authors
HL Elliott
British Journal of Clinical Pharmacology
1991
Corpus ID: 28381222
1. UK-68,798, a novel class III anti-arrhythmic agent was administered intravenously to twelve healthy volunteers in a placebo…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE